[摘要] 目的 研究重復经颅磁刺激联合曲唑酮治疗伴有睡眠问题的焦虑障碍患者疗效，为临床治疗提供有效依据。方法 随机选取2017年1月—2018年12月该院接诊的90例伴有睡眠问题的焦虑障碍患者，按照随机数表法将其分为实验组与对照组，每组45例，对照组予以曲唑酮治疗，实验组予以曲唑酮联合重复经颅磁刺激治疗，两组治疗周期均为6周。调查两组患者治疗前后匹兹堡睡眠量表(PSQI)和汉密尔顿焦虑量表(HAMA)评分变化状况，并对两组患者治疗后临床疗效进行分析。结果 两组患者一般资料相比较差异无统计学意义(P>0.05)。两组患者治疗前的HAMA、PSQI量表评分均差异无统计学意义(P>0.05);治疗后实验组患者HAMA量表评分分别为(6.1±3.3)分、PSQI(6.8±3.2)分均优于对照组，两组对比差异有统计学意义(t=3.625 8、4.331 2，P, http://www.100md.com
 [关键词] 重复经颅磁刺激;曲唑酮;焦虑障碍;失眠

 [中图分类号] R4 [文献标识码] A [文章编号] 1674-0742(2019)09(a)-0118-03

 [Abstract] Objective To study the efficacy of repetitive transcranial magnetic stimulation combined with trazodone in the treatment of anxiety disorders with sleep problems， and provide an effective basis for clinical treatment. Methods A total of 90 patients with anxiety disorders who were admitted to our hospital from January 2017 to December 2018 were randomly selected. The patients were divided into experimental group and control group according to the random number table method， 45 cases in each group. The control group was treated with trazodone， the experimental group was treated with trazodone combined with transcranial magnetic stimulation. The treatment period was 6 weeks. The changes of Pittsburgh Sleep Scale (PSQI) and Hamilton Anxiety Scale (HAMA) scores before and after treatment were investigated， and the clinical effects of the two groups were analyzed. Results There was no significant difference in the general data between the two groups (P>0.05). There was no statistically significant difference in the HAMA and PSQI scores between the two groups before treatment (P>0.05). After treatment， the HAMA scale scores of the experimental group were (6.1±3.3)points and PSQI (6.8±3.2)points better than the control group， the difference were statistically significant (t=3.625 8， 4.331 2， P, http://www.100md.com(杨茂增 何秀贞 梁光辉 夏韵妍 卢圳耿) 第 1 2 3 页 下一页
 百拇医药网 http://www.100md.com/html/paper/1674-0742/2019/25/38.htm